11.08.2011 • NewsLanxessQ2 2011Axel Heitmann

Lanxess Posts €181 Million Q2 Net Income

Lanxess posted second quarter net income of €181 million or €2.17 per share, up from €131 million or €1.57 per share last year. EBITDA pre exceptionals in the second quarter rose 26% year-over-year to €339 million.

Sales grew to €2.24 billion from €1.83 billion in the prior-year quarter. Lanxess said it implemented price increases in all segments in order to fully pass on higher raw material costs. In addition, there was volume growth and positive portfolio effects from recent acquisitions, above all the EPDM rubber business DSM Elastomers. Sales grew despite negative currency effects at minus 7% mainly due to a weak U.S. dollar.

"Demand for our products remains strong and plants are running at very high capacity utilization rates," said CEO Axel Heitmann. "Against this background and the strong first half of the year, we are lifting our full-year earnings guidance."

EBITDA pre exceptionals is now expected to grow about 20% year-on-year compared to €918 million in 2010. Earlier, EBITDA pre exceptionals were expected to grow 10-15%.

 

Company

Logo:

LANXESS Deutschland GmbH

Kennedyplatz 1
50569 Köln
Germany

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Digital Validation
Transforming from Paper to Digital

Digital Validation

Our experts will delve into the recently released International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Digital Validation